Prospective RBC phenotype matching ina stroke-Prevention trial in sickle cell anemia: A multicenter transfusion trial

Elliott P. Vichinsky, Naomi L C Luban, Elizabeth Wright, Nancy Olivieri, Catherine Driscoll, Charles H. Pegelow, Robert J. Adams

Research output: Contribution to journalArticle

234 Citations (Scopus)

Abstract

BACKGROUND: Most sickle cell anemia patients undergo transfusion therapy to prevent complications. The Stroke Prevention Trial in Sickle Cell Anemia showed that transfusion therapy is effective in the primary prevention of stroke. Despite its efficacy, transfusion therapy is limited by alloimmunization. The purpose of this study was to determine if a multicenter trial could implement a transfusion program utilizing phenotypically matched blood to reduce alloimmunization. STUDY DESIGN AND METHODS: One hundred thirty children underwent RBC phenotyping and antibody screening with review of blood bank records. The protocol required use of WBC-reduced RBCs, which were matched for E, C, and Kell. Monthly alloantibody testing and review of transfusion forms were performed to determine compliance and the occurrence of any adverse events. RESULTS: Patient RBCs expressed a low frequency of Kell (2%), E (20%), and C (25%) antigens. Sixty-one patients received 1830 units. Ninety-seven percent of all units were WBC reduced. Only 29 units were inadvertently not matched for E, C, and Kell. Five patients (8%) developed a clinically significant alloantibody. Four developed a single antibody to E or Kell. Three patients (5%) developed a warm autoantibody. There were 11 transfusion reactions and 8 transfusion-associated events. Transfusion reactions included 6 febrile reactions (0.33%/unit), 3 allergic (0.16%/unit), and 2 hemolytic (0.11%/unit). Associated events included 4 episodes of hypertension (0.22%/unit), 3 crises (0.16%/unit), and 1 transient ischemic attack (0.05%/unit). CONCLUSION: This is the first multicenter study to show that extended RBC phenotyping can be implemented nationwide. Compared to studies, the alloimmunization rate dropped from 3 percent to 0.5 percent per unit, and hemolytic transfusion reactions dropped by 90 percent. It is recommended that all transfused sickle cell anemia patients be antigen matched for E, C, and Kell. Patients should be closely monitored during transfusions to avoid preventable risks.

Original languageEnglish (US)
Pages (from-to)1086-1092
Number of pages7
JournalTransfusion
Volume41
Issue number9
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Multicenter Studies
Stroke
Phenotype
Isoantibodies
Antigens
Blood Banks
Antibodies
Transient Ischemic Attack
Primary Prevention
indium arsenide
Autoantibodies
Compliance
Fever
Therapeutics
Hypertension
Transfusion Reaction

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Vichinsky, E. P., Luban, N. L. C., Wright, E., Olivieri, N., Driscoll, C., Pegelow, C. H., & Adams, R. J. (2001). Prospective RBC phenotype matching ina stroke-Prevention trial in sickle cell anemia: A multicenter transfusion trial. Transfusion, 41(9), 1086-1092. https://doi.org/10.1046/j.1537-2995.2001.41091086.x

Prospective RBC phenotype matching ina stroke-Prevention trial in sickle cell anemia : A multicenter transfusion trial. / Vichinsky, Elliott P.; Luban, Naomi L C; Wright, Elizabeth; Olivieri, Nancy; Driscoll, Catherine; Pegelow, Charles H.; Adams, Robert J.

In: Transfusion, Vol. 41, No. 9, 2001, p. 1086-1092.

Research output: Contribution to journalArticle

Vichinsky, EP, Luban, NLC, Wright, E, Olivieri, N, Driscoll, C, Pegelow, CH & Adams, RJ 2001, 'Prospective RBC phenotype matching ina stroke-Prevention trial in sickle cell anemia: A multicenter transfusion trial', Transfusion, vol. 41, no. 9, pp. 1086-1092. https://doi.org/10.1046/j.1537-2995.2001.41091086.x
Vichinsky, Elliott P. ; Luban, Naomi L C ; Wright, Elizabeth ; Olivieri, Nancy ; Driscoll, Catherine ; Pegelow, Charles H. ; Adams, Robert J. / Prospective RBC phenotype matching ina stroke-Prevention trial in sickle cell anemia : A multicenter transfusion trial. In: Transfusion. 2001 ; Vol. 41, No. 9. pp. 1086-1092.
@article{7b14493e87174ecaa4c852c2245f53a8,
title = "Prospective RBC phenotype matching ina stroke-Prevention trial in sickle cell anemia: A multicenter transfusion trial",
abstract = "BACKGROUND: Most sickle cell anemia patients undergo transfusion therapy to prevent complications. The Stroke Prevention Trial in Sickle Cell Anemia showed that transfusion therapy is effective in the primary prevention of stroke. Despite its efficacy, transfusion therapy is limited by alloimmunization. The purpose of this study was to determine if a multicenter trial could implement a transfusion program utilizing phenotypically matched blood to reduce alloimmunization. STUDY DESIGN AND METHODS: One hundred thirty children underwent RBC phenotyping and antibody screening with review of blood bank records. The protocol required use of WBC-reduced RBCs, which were matched for E, C, and Kell. Monthly alloantibody testing and review of transfusion forms were performed to determine compliance and the occurrence of any adverse events. RESULTS: Patient RBCs expressed a low frequency of Kell (2{\%}), E (20{\%}), and C (25{\%}) antigens. Sixty-one patients received 1830 units. Ninety-seven percent of all units were WBC reduced. Only 29 units were inadvertently not matched for E, C, and Kell. Five patients (8{\%}) developed a clinically significant alloantibody. Four developed a single antibody to E or Kell. Three patients (5{\%}) developed a warm autoantibody. There were 11 transfusion reactions and 8 transfusion-associated events. Transfusion reactions included 6 febrile reactions (0.33{\%}/unit), 3 allergic (0.16{\%}/unit), and 2 hemolytic (0.11{\%}/unit). Associated events included 4 episodes of hypertension (0.22{\%}/unit), 3 crises (0.16{\%}/unit), and 1 transient ischemic attack (0.05{\%}/unit). CONCLUSION: This is the first multicenter study to show that extended RBC phenotyping can be implemented nationwide. Compared to studies, the alloimmunization rate dropped from 3 percent to 0.5 percent per unit, and hemolytic transfusion reactions dropped by 90 percent. It is recommended that all transfused sickle cell anemia patients be antigen matched for E, C, and Kell. Patients should be closely monitored during transfusions to avoid preventable risks.",
author = "Vichinsky, {Elliott P.} and Luban, {Naomi L C} and Elizabeth Wright and Nancy Olivieri and Catherine Driscoll and Pegelow, {Charles H.} and Adams, {Robert J.}",
year = "2001",
doi = "10.1046/j.1537-2995.2001.41091086.x",
language = "English (US)",
volume = "41",
pages = "1086--1092",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Prospective RBC phenotype matching ina stroke-Prevention trial in sickle cell anemia

T2 - A multicenter transfusion trial

AU - Vichinsky, Elliott P.

AU - Luban, Naomi L C

AU - Wright, Elizabeth

AU - Olivieri, Nancy

AU - Driscoll, Catherine

AU - Pegelow, Charles H.

AU - Adams, Robert J.

PY - 2001

Y1 - 2001

N2 - BACKGROUND: Most sickle cell anemia patients undergo transfusion therapy to prevent complications. The Stroke Prevention Trial in Sickle Cell Anemia showed that transfusion therapy is effective in the primary prevention of stroke. Despite its efficacy, transfusion therapy is limited by alloimmunization. The purpose of this study was to determine if a multicenter trial could implement a transfusion program utilizing phenotypically matched blood to reduce alloimmunization. STUDY DESIGN AND METHODS: One hundred thirty children underwent RBC phenotyping and antibody screening with review of blood bank records. The protocol required use of WBC-reduced RBCs, which were matched for E, C, and Kell. Monthly alloantibody testing and review of transfusion forms were performed to determine compliance and the occurrence of any adverse events. RESULTS: Patient RBCs expressed a low frequency of Kell (2%), E (20%), and C (25%) antigens. Sixty-one patients received 1830 units. Ninety-seven percent of all units were WBC reduced. Only 29 units were inadvertently not matched for E, C, and Kell. Five patients (8%) developed a clinically significant alloantibody. Four developed a single antibody to E or Kell. Three patients (5%) developed a warm autoantibody. There were 11 transfusion reactions and 8 transfusion-associated events. Transfusion reactions included 6 febrile reactions (0.33%/unit), 3 allergic (0.16%/unit), and 2 hemolytic (0.11%/unit). Associated events included 4 episodes of hypertension (0.22%/unit), 3 crises (0.16%/unit), and 1 transient ischemic attack (0.05%/unit). CONCLUSION: This is the first multicenter study to show that extended RBC phenotyping can be implemented nationwide. Compared to studies, the alloimmunization rate dropped from 3 percent to 0.5 percent per unit, and hemolytic transfusion reactions dropped by 90 percent. It is recommended that all transfused sickle cell anemia patients be antigen matched for E, C, and Kell. Patients should be closely monitored during transfusions to avoid preventable risks.

AB - BACKGROUND: Most sickle cell anemia patients undergo transfusion therapy to prevent complications. The Stroke Prevention Trial in Sickle Cell Anemia showed that transfusion therapy is effective in the primary prevention of stroke. Despite its efficacy, transfusion therapy is limited by alloimmunization. The purpose of this study was to determine if a multicenter trial could implement a transfusion program utilizing phenotypically matched blood to reduce alloimmunization. STUDY DESIGN AND METHODS: One hundred thirty children underwent RBC phenotyping and antibody screening with review of blood bank records. The protocol required use of WBC-reduced RBCs, which were matched for E, C, and Kell. Monthly alloantibody testing and review of transfusion forms were performed to determine compliance and the occurrence of any adverse events. RESULTS: Patient RBCs expressed a low frequency of Kell (2%), E (20%), and C (25%) antigens. Sixty-one patients received 1830 units. Ninety-seven percent of all units were WBC reduced. Only 29 units were inadvertently not matched for E, C, and Kell. Five patients (8%) developed a clinically significant alloantibody. Four developed a single antibody to E or Kell. Three patients (5%) developed a warm autoantibody. There were 11 transfusion reactions and 8 transfusion-associated events. Transfusion reactions included 6 febrile reactions (0.33%/unit), 3 allergic (0.16%/unit), and 2 hemolytic (0.11%/unit). Associated events included 4 episodes of hypertension (0.22%/unit), 3 crises (0.16%/unit), and 1 transient ischemic attack (0.05%/unit). CONCLUSION: This is the first multicenter study to show that extended RBC phenotyping can be implemented nationwide. Compared to studies, the alloimmunization rate dropped from 3 percent to 0.5 percent per unit, and hemolytic transfusion reactions dropped by 90 percent. It is recommended that all transfused sickle cell anemia patients be antigen matched for E, C, and Kell. Patients should be closely monitored during transfusions to avoid preventable risks.

UR - http://www.scopus.com/inward/record.url?scp=0034858110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034858110&partnerID=8YFLogxK

U2 - 10.1046/j.1537-2995.2001.41091086.x

DO - 10.1046/j.1537-2995.2001.41091086.x

M3 - Article

C2 - 11552063

AN - SCOPUS:0034858110

VL - 41

SP - 1086

EP - 1092

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 9

ER -